Table Info

Table 1.

COVID-19 vaccines granted EUL by the WHO as of December 2, 2022 [26, 27]

No.	Vaccine	Platform	Company	Number of approved countries^a	EUL date
1	Comirnaty	mRNA	Pfizer/BioNTech	149	December 31, 2020
2	Covishield^b	Non-replicating viral vector	Serum Institute of India	49	February 15, 2021
3	Vaxzevria	Non-replicating viral vector	AstraZeneca	149	February 15, 2021
4	Jcovden	Non-replicating viral vector	Johnson and Johnson	113	March 12, 2021
5	Spikevax	mRNA	Moderna	88	April 30, 2021
6	Covilo	Inactivated	Sinopharm	93	May 7, 2021
7	CoronaVac	Inactivated	Sinovac	56	June 1, 2021
8	Covaxin	Inactivated	Bharat Biotech	14	November 3, 2021
9	Covovax^c	Protein subunit	Serum Institute of India	6	December 17, 2021
10	Nuvaxovid	Protein subunit	Novavax	40	December 20, 2021
11	Convidecia	Non-replicating viral vector	CanSino	10	May 19, 2022

^a The vaccine was approved, authorized, licensed, granted EUA, or made available for use by a regulatory agency, a national authority, or another entity; ^b Covishield has the same formulation of Vaxzevria; ^c Covovax has the same formulation of Nuvaxovid

Declarations

Author contributions

SO: Conceptualization, Visualization, Writing—original draft, Writing—review & editing.

Conflicts of interest

The author declares that he has no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Chavda VP, Hossain MK, Beladiya J, Apostolopoulos V. Nucleic acid vaccines for COVID-19: a paradigm shift in the vaccine development arena. Biologics. 2021;1:337–56. [DOI]

Mugunthan SP, Kannan G, Chandra HM, Paital B. Infection, transmission, pathogenesis and vaccine development against Mycoplasma gallisepticum. Vaccines (Basel). 2023;11:469. [DOI] [PubMed] [PMC]

Amanpour S. The rapid development and early success of covid 19 vaccines have raised hopes for accelerating the cancer treatment mechanism. Arch Razi Inst. 2021;76:1–6. [DOI] [PubMed] [PMC]

Koritala T, Hussain A, Pleshkova Y, Dondapati L, Tirupathi R, Rabaan AA, et al. A narrative review of emergency use authorization versus full FDA approval and its effect on COVID-19 vaccination hesitancy. Infez Med. 2021;29:339–44. [DOI] [PubMed] [PMC]

Stern PL. Key steps in vaccine development. Ann Allergy Asthma Immunol. 2020;125:17–27. [DOI] [PubMed]

Step 3: clinical research [Internet]. [cited 2023 Feb 9]. Available from: https://www.fda.gov/patients/drug-development-process/step-3-clinical-research

Lurie N, Saville M, Hatchett R, Halton J. Developing covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382:1969–73. [DOI] [PubMed]

Borse RH, Shrestha SS, Fiore AE, Atkins CY, Singleton JA, Furlow C, et al. Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009–2010. Emerg Infect Dis. 2013;19:439–48. [DOI] [PubMed] [PMC]

Past flu pandemics [Internet]. [cited 2023 Feb 9]. Available from: https://www.cdc.gov/flu/pandemic-resources/basics/past-pandemics.html

10.

Wei CJ, Boyington JC, Dai K, Houser KV, Pearce MB, Kong WP, et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med. 2010;2:24ra21. [DOI] [PubMed] [PMC]

11.

Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:2405–13. [DOI] [PubMed]

12.

Centers for Disease Control and Prevention (CDC). Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep. 2009;58:1100–1. [PubMed]

13.

Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat Med. 2021;27:591–600. [DOI] [PubMed]

14.

2014-2016 Ebola outbreak in West Africa [Internet]. [cited 2023 Feb 9]. Available from: https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html

15.

First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response [Internet]. [cited 2023 Feb 9]. Available from: https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health

16.

Ervebo [Internet]. Amsterdam: European Medicines Agency; c1995–2023 [cited 2023 Feb 9]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ervebo

17.

Das K, Pingali MS, Paital B, Panda F, Pati SG, Singh A, et al. A detailed review of the outbreak of COVID-19. Front Biosci (Landmark Ed). 2021;26:149–70. [DOI] [PubMed]

18.

Kupferschmidt K, Cohen J. Will novel virus go pandemic or be contained? Science. 2020;367:610–1. [DOI] [PubMed]

19.

Thompson R. Pandemic potential of 2019-nCoV. Lancet Infect Dis. 2020;20:280. [DOI] [PubMed] [PMC]

20.

Coronavirus disease (COVID-19) pandemic [Internet]. WHO; c2023 [cited 2023 Feb 9]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

21.

Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157–60. [DOI] [PubMed] [PMC]

22.

Weekly epidemiological update on COVID-19 - 1 February 2023 [Internet]. WHO; c2023 [cited 2023 Feb 9]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-february-2023

23.

Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, et al. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther. 2022;7:146. [DOI] [PubMed] [PMC]

24.

Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81:495–501. [DOI] [PubMed] [PMC]

25.

Carneiro DC, Sousa JD, Monteiro-Cunha JP. The COVID-19 vaccine development: a pandemic paradigm. Virus Res. 2021;301:198454. [DOI] [PubMed] [PMC]

26.

Coronavirus disease (COVID-19): vaccines and vaccine safety [Internet]. WHO; c2023 [cited 2023 Feb 9]. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines

27.

11 vaccines granted emergency use listing (EUL) by WHO [Internet]. VIPER Group COVID19 Vaccine Tracker Team; c2023 [cited 2023 Feb 9]. Available from: https://covid19.trackvaccines.org/agency/who

28.

Paul E, Brown GW, Ridde V. COVID-19: time for paradigm shift in the nexus between local, national and global health. BMJ Glob Health. 2020;5:e002622. [DOI] [PubMed] [PMC]

29.

Emergency use authorization for vaccines explained [Internet]. [cited 2023 Feb 9]. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained

30.

Bloom DE, Cadarette D, Ferranna M, Hyer RN, Tortorice DL. How new models of vaccine development for COVID-19 have helped address an epic public health crisis. Health Aff (Millwood). 2021;40:410–8. [DOI] [PubMed]

31.

Slaoui M, Hepburn M. Developing safe and effective covid vaccines—Operation Warp Speed’s strategy and approach. N Engl J Med. 2020;383:1701–3. [DOI] [PubMed]

32.

Emergency use authorization of medical products and related authorities [Internet]. [cited 2023 Feb 9]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities

33.

FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine [Internet]. [cited 2023 Feb 9]. Available from: https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19

34.

Wiysonge CS, Ndwandwe D, Ryan J, Jaca A, Batouré O, Anya BM, et al. Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future? Hum Vaccin Immunother. 2022;18:1–3. [DOI] [PubMed] [PMC]

35.

McKee C, Bohannon K. Exploring the reasons behind parental refusal of vaccines. J Pediatr Pharmacol Ther. 2016;21:104–9. [DOI] [PubMed] [PMC]

36.

Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. Public Health. 2021;194:245–51. [DOI] [PubMed] [PMC]

37.

Peters MDJ. Addressing vaccine hesitancy and resistance for COVID-19 vaccines. Int J Nurs Stud. 2022;131:104241. [DOI] [PubMed] [PMC]

38.

Joshi A, Kaur M, Kaur R, Grover A, Nash D, El-Mohandes A. Predictors of COVID-19 vaccine acceptance, intention, and hesitancy: a scoping review. Front Public Health. 2021;9:698111. [DOI] [PubMed] [PMC]

39.

Fisher CB, Bragard E, Jaber R, Gray A. COVID-19 vaccine hesitancy among parents of children under five years in the United States. Vaccines (Basel). 2022;10:1313. [DOI] [PubMed] [PMC]

40.

Carcelen AC, Prosperi C, Mutembo S, Chongwe G, Mwansa FD, Ndubani P, et al. COVID-19 vaccine hesitancy in Zambia: a glimpse at the possible challenges ahead for COVID-19 vaccination rollout in sub-Saharan Africa. Hum Vaccin Immunother. 2022;18:1–6. [DOI] [PubMed] [PMC]

41.

Diaz P, Reddy P, Ramasahayam R, Kuchakulla M, Ramasamy R. COVID-19 vaccine hesitancy linked to increased internet search queries for side effects on fertility potential in the initial rollout phase following emergency use authorization. Andrologia. 2021;53:e14156. [DOI] [PubMed] [PMC]